NRSN vs. TNXP, EDSA, VINC, FLGC, TRAW, HUGE, PIRS, RDHL, TLPH, and NERV
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Tonix Pharmaceuticals (TNXP), Edesa Biotech (EDSA), Vincerx Pharma (VINC), Flora Growth (FLGC), Traws Pharma (TRAW), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), RedHill Biopharma (RDHL), Talphera (TLPH), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
NeuroSense Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tonix Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 2,920.32%. Given Tonix Pharmaceuticals' higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than NeuroSense Therapeutics.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Tonix Pharmaceuticals' return on equity of -80.63% beat NeuroSense Therapeutics' return on equity.
NeuroSense Therapeutics has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.
In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 3 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.96 beat Tonix Pharmaceuticals' score of 0.70 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.
Tonix Pharmaceuticals received 337 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 63.84% of users gave Tonix Pharmaceuticals an outperform vote.
Summary
Tonix Pharmaceuticals beats NeuroSense Therapeutics on 10 of the 15 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroSense Therapeutics Competitors List
Related Companies and Tools
